A Pilot Study, Evaluating the Efficacy of Regulatory T-cell Suppression by Ontak in Metastatic Pancreatic Cancer

NCT00726037 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

7

Enrollment

OTHER

Sponsor class

Stopped Collaborator withdrew support due to a drug supply interruption.

Conditions

Metastatic Pancreatic Cancer

Interventions

DRUG: Ontak

Sponsor

Loyola University

Collaborators

[object Object]
[object Object]